Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• Sickle cell disease (SCD) is a genetic disorder affecting beta-globin.
• Hyperhemolysis (HS) is a severe complication in SCD, causing rapid destruction of red blood cells.

Purpose of the Study:

• To review the clinical presentation, diagnosis, pathogenesis, and management of HS in SCD patients.
• To highlight the empirical nature of current HS treatments and the need for standardized protocols.

Main Methods:

• Literature review of clinical presentations, diagnostic markers, and treatment strategies for HS in SCD.
• Analysis of immunohematological findings and response to various therapeutic agents.

Main Results:

• HS presents with severe anemia, jaundice, hemoglobinuria, and hemodynamic instability.
• Diagnosis is complicated by variable symptoms and delayed immunohematological test positivity.
• Current management relies on empirical first-line treatments like steroids and IVIG, with varied responses to other agents.

Conclusions:

• Effective management of HS in SCD requires further investigation and robust clinical trials.
• Standardized treatment protocols are needed to improve outcomes for SCD patients experiencing HS.